Feb 14, 2023 / 02:20PM GMT
David Reed Risinger - Leerink Partners LLC, Research Division - Senior MD
So good morning, everybody, and thank you for joining our session with Regeneron. My name is Dave Risinger. I'm responsible for diversified biopharmaceuticals coverage at SVB Securities. And on behalf of the firm, it's very much my pleasure to welcome senior executives from Regeneron.
So with us today, we have Izzy Lowy, who is Senior Vice President of Clinical Development for Oncology; Andres Sirulnik, Senior Vice President of Clinical Development for Hematology; and Ryan Crowe, Vice President of Investor Relations.
And so with that, let me turn it over to Ryan to read some disclaimers and then we'll take it from there.
Ryan Crowe - Regeneron Pharmaceuticals, Inc. - VP of IR
Thanks, Dave. It's great to be here, and I appreciate the invitation to present at the SVB Securities Global Biopharma Conference.
Before we start, I'd like to remind you that remarks made today may include forward-looking statements about Regeneron. Each forward-looking statement is
Regeneron Pharmaceuticals Inc at SVB Securities Global Biopharma Conference (Virtual) Transcript
Feb 14, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers